ARIA‐EAACI statement on severe allergic reactions to COVID‐19 vaccines–an EAACI‐ARIA position paper

L Klimek, M Jutel, CA Akdis, J Bousquet, M Akdis… - Allergy, 2021 - Wiley Online Library
Further to the approval of the Coronavirus disease 2019 (COVID‐19) vaccine BNT162b2,
several severe anaphylaxis cases occured within the first few days of public vaccination. An …
被引用次数：104 相关文章

ARIA-EAACI statement on severe allergic reactions to COVID-19 vaccines--an EAACI-ARIA Position Paper

L Klimek, M Jutel, C Akdis, J Bousquet, M Akdis… - Authorea …, 2020 - techrxiv.org
Coronavirus disease 2019 (COVID-19) vaccine BNT162b2 received approval and within the
first few days of public vaccination several severe anaphylaxis cases occurred. An …

ARIA-EAACI statement on severe allergic reactions to COVID-19 vaccines-An EAACI-ARIA Position Paper.

L Klimek, M Jutel, CA Akdis, J Bousquet, M Akdis… - 2021 - mediatum.ub.tum.de
Further to the approval of the Coronavirus disease 2019 (COVID-19) vaccine BNT162b2,
several severe anaphylaxis cases occured within the first few days of public vaccination. An …

ARIA-EAACI statement on severe allergic reactions to COVID-19 vaccines-An EAACI-ARIA Position Paper.

L Klimek, M Jutel, CA Akdis, J Bousquet, M Akdis… - Allergy, 2021 - europepmc.org
Further to the approval of the Coronavirus disease 2019 (COVID-19) vaccine BNT162b2,
several severe anaphylaxis cases occured within the first few days of public vaccination. An …

ARIA-EAACI statement on severe allergic reactions to COVID-19 vaccines--an EAACI-ARIA Position Paper

L Klimek, M Jutel, C Akdis, J Bousquet… - Authorea …, 2020 - advance.sagepub.com
Coronavirus disease 2019 (COVID-19) vaccine BNT162b2 received approval and within the
first few days of public vaccination several severe anaphylaxis cases occurred. An …

ARIA‐EAACI statement on severe allergic reactions to COVID‐19 vaccines–An EAACI‐ARIA Position Paper.

L Klimek, M Jutel, CA Akdis, J Bousquet, M Akdis… - Allergy, 2021 - search.ebscohost.com
Further to the approval of the Coronavirus disease 2019 (COVID‐19) vaccine BNT162b2,
several severe anaphylaxis cases occured within the first few days of public vaccination. An …

ARIA-EAACI statement on severe allergic reactions to COVID-19 vaccines--an EAACI-ARIA Position Paper

L Klimek, M Jutel, C Akdis, J Bousquet… - Authorea …, 2020 - essopenarchive.org
Coronavirus disease 2019 (COVID-19) vaccine BNT162b2 received approval and within the
first few days of public vaccination several severe anaphylaxis cases occurred. An …

ARIA‐EAACI statement on severe allergic reactions to COVID‐19 vaccines–An EAACI‐ARIA Position Paper

L Klimek, M Jutel, C Akdis, J Bousquet, M Akdis… - Allergy, 2021 - hal.science
Further to the approval of the Coronavirus disease 2019 (COVID-19) vaccine BNT162b2,
several severe anaphylaxis cases occured within the first few days of public vaccination. An …

ARIA‐EAACI statement on severe allergic reactions to COVID‐19 vaccines–An EAACI‐ARIA Position Paper

L Klimek, M Jutel, CA Akdis, J Bousquet, M Akdis… - Allergy, 2021 - zora.uzh.ch
Further to the approval of the Coronavirus disease 2019 (COVID-19) vaccine BNT162b2,
several severe anaphylaxis cases occured within the first few days of public vaccination. An …

ARIA-EAACI statement on severe allergic reactions to COVID-19 vaccines-An EAACI-ARIA Position Paper

L Klimek, M Jutel, CA Akdis, J Bousquet, M Akdis… - …, 2021 - pubmed.ncbi.nlm.nih.gov
Further to the approval of the Coronavirus disease 2019 (COVID-19) vaccine BNT162b2,
several severe anaphylaxis cases occured within the first few days of public vaccination. An …